BioNxt Accelerates R&D with Move to Gen-Plus Laboratory in Munich, Germany, Expanding Drug Delivery Research Capabilities
BioNxt Solutions (CSE:BNXT)(OTC:BNXTF) has announced its relocation to the Gen-Plus Contract Research and Development Organization in Munich, Germany, with operations set to begin on March 1, 2025. The move provides access to a 1,000-square-meter research facility equipped with state-of-the-art technologies for high-potency active pharmaceutical ingredients and GMP-compliant processes.
The strategic relocation aims to enhance R&D capabilities, particularly in drug delivery systems, neurodegenerative disease therapeutics, and next-generation biomedical technologies. The facility features specialized equipment for solid and semi-solid dosage forms and drug printing capabilities. The Munich location also offers opportunities for collaboration with leading research institutions, biotech firms, and academic experts.
BioNxt Solutions (CSE:BNXT)(OTC:BNXTF) ha annunciato il suo trasferimento alla Gen-Plus Contract Research and Development Organization a Monaco di Baviera, Germania, con operazioni programmate per iniziare il 1 marzo 2025. Questo trasferimento fornisce accesso a una struttura di ricerca di 1.000 metri quadrati dotata di tecnologie all'avanguardia per ingredienti farmaceutici attivi ad alta potenza e processi conformi alle GMP.
Il trasferimento strategico mira a potenziare le capacità di R&S, in particolare nei sistemi di somministrazione dei farmaci, nelle terapie per le malattie neurodegenerative e nelle tecnologie biomediche di prossima generazione. La struttura è dotata di attrezzature specializzate per forme farmaceutiche solide e semisolide e capacità di stampa dei farmaci. La posizione di Monaco offre anche opportunità di collaborazione con istituzioni di ricerca di primo piano, aziende biotech e esperti accademici.
BioNxt Solutions (CSE:BNXT)(OTC:BNXTF) ha anunciado su traslado a la Gen-Plus Contract Research and Development Organization en Múnich, Alemania, con operaciones que comenzarán el 1 de marzo de 2025. Este traslado proporciona acceso a una instalación de investigación de 1,000 metros cuadrados equipada con tecnologías de vanguardia para ingredientes farmacéuticos activos de alta potencia y procesos conformes a GMP.
El traslado estratégico tiene como objetivo mejorar las capacidades de I+D, especialmente en sistemas de entrega de medicamentos, terapias para enfermedades neurodegenerativas y tecnologías biomédicas de nueva generación. La instalación cuenta con equipos especializados para formas de dosificación sólidas y semisólidas, así como capacidades de impresión de medicamentos. La ubicación en Múnich también ofrece oportunidades de colaboración con instituciones de investigación líderes, empresas biotecnológicas y expertos académicos.
BioNxt Solutions (CSE:BNXT)(OTC:BNXTF)는 독일 뮌헨에 위치한 Gen-Plus Contract Research and Development Organization으로 이전한다고 발표했으며, 운영 시작일은 2025년 3월 1일입니다. 이 이전으로 1,000제곱미터 규모의 최신 기술이 갖춰진 연구 시설에 접근할 수 있게 되며, 고강도 활성 제약 성분 및 GMP 준수 공정을 위한 시설입니다.
전략적 이전은 특히 약물 전달 시스템, 신경퇴행성 질환 치료제, 차세대 생의학 기술 분야에서 R&D 역량을 향상시키는 것을 목표로 하고 있습니다. 이 시설은 고체 및 반고체 제형에 대한 전문 장비와 약물 인쇄 기능을 갖추고 있습니다. 뮌헨 지역에서는 선도적인 연구 기관, 생명공학 회사 및 학문적 전문가들과의 협업 기회도 제공합니다.
BioNxt Solutions (CSE:BNXT)(OTC:BNXTF) a annoncé son déménagement vers la Gen-Plus Contract Research and Development Organization à Munich, en Allemagne, avec un début des opérations prévu pour le 1er mars 2025. Ce déménagement offre un accès à une installation de recherche de 1 000 mètres carrés équipée de technologies de pointe pour les ingrédients pharmaceutiques actifs à haute puissance et des processus conformes aux BPF.
Ce déménagement stratégique vise à renforcer les capacités de R&D, notamment dans les systèmes de délivrance de médicaments, les thérapies pour les maladies neurodégénératives et les technologies biomédicales de nouvelle génération. L'installation dispose d'équipements spécialisés pour les formes posologiques solides et semi-solides ainsi que de capacités d'impression de médicaments. L'emplacement à Munich offre également des opportunités de collaboration avec des institutions de recherche de premier plan, des entreprises biopharmaceutiques et des experts académiques.
BioNxt Solutions (CSE:BNXT)(OTC:BNXTF) hat seinen Umzug zur Gen-Plus Contract Research and Development Organization in München, Deutschland, angekündigt, mit Betriebsbeginn am 1. März 2025. Der Umzug ermöglicht den Zugang zu einer 1.000 Quadratmeter großen Forschungseinrichtung, die mit modernster Technologie für hochpotente aktive pharmazeutische Wirkstoffe und GMP-konforme Prozesse ausgestattet ist.
Der strategische Umzug zielt darauf ab, die F&E-Kapazitäten zu verbessern, insbesondere in den Bereichen Arzneimittellieferungssysteme, Therapeutika für neurodegenerative Erkrankungen und Biomedical-Technologien der nächsten Generation. Die Einrichtung verfügt über spezialisierte Geräte für feste und halbfeste Darreichungsformen sowie über Druckmöglichkeiten für Medikamente. Der Standort München bietet außerdem Möglichkeiten zur Zusammenarbeit mit führenden Forschungsinstitutionen, Biotech-Unternehmen und akademischen Experten.
- Access to advanced 1,000-square-meter research facility with state-of-the-art equipment
- Strategic location in Munich's biotech hub enabling research partnerships
- Enhanced capabilities for high-potency pharmaceutical development and GMP processes
- Potential acceleration of preclinical research timelines
- None.
VANCOUVER, BC / ACCESS Newswire / January 21, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, is excited to announce a major milestone in its research and development journey. The company is transitioning its cutting-edge R&D activities to the Gen-Plus Contract Research and Development Organization (CRDO) in Munich, Germany, with operations scheduled to begin on March 1, 2025. This move underscores BioNxt's commitment to scientific innovation and advancing solutions for unmet medical needs.
The new laboratory facility provides BioNxt with access to cutting-edge technologies, an expanded 1,000-square-meter research environment, and strategic opportunities for scientific collaboration within Europe's biotech hub. The transition is expected to accelerate the company's ongoing projects, particularly in the areas of drug delivery systems, neurodegenerative disease therapeutics, and next-generation biomedical technologies.
BioNxt Relocates to Gen-Plus: Strategic Importance for Advanced R&D
By leveraging the advanced and innovative infrastructure of the Gen-Plus Laboratory, BioNxt aims to harness the facility's 1,000 square meters of state-of-the-art space designed for high-potency active pharmaceutical ingredients and GMP-compliant processes. The lab's specialized equipment, including advanced technologies for solid and semi-solid dosage forms and capabilities in drug printing, will empower BioNxt to:
Enhance R&D Capabilities: With access to cutting-edge equipment and analytical tools, BioNxt is better positioned to develop innovative solutions and optimize its research outcomes.
Foster Collaborations: The Munich location enables proximity to leading research institutions, biotech firms, and academic experts, paving the way for impactful partnerships.
Accelerate Innovation: The advanced resources at Gen-Plus Laboratory allow BioNxt to streamline workflows and reduce the time to bring groundbreaking therapies to market.
"BioNxt's transition to Gen-Plus marks a pivotal moment for BioNxt," said Hugh Rogers, CEO of BioNxt Solutions Inc. "This transition is both strategic and timely, and unlocking new possibilities for added strength on IP with innovation and reinforcing our mission to deliver transformative therapies for patients worldwide. We are thrilled about the opportunities that this new chapter brings, providing Impact on Current and Future projects."
BioNxt's innovative projects, including the development of advanced drug delivery systems such as sublingual thin films, transdermal patches, and other targeted therapeutic platforms, stand to gain significant advantages from the advanced capabilities at the Gen-Plus Laboratory. This cutting-edge facility is poised to accelerate preclinical research timelines, enhance formulation accuracy, and streamline the development of next-generation therapeutics.
About Gen-Plus GmbH & Co. KG
Gen-Plus GmbH & Co. KG, headquartered in Munich, Germany, is a premier Contract Research and Development Organization (CRDO) with over 25 years of experience in pharmaceutical formulation and development. The company operates a 1,000-square-meter state-of-the-art laboratory equipped for handling high-potency active pharmaceutical ingredients and licensed for GMP-compliant production, including narcotics.
Gen-Plus specializes in developing solid and semi-solid dosage forms, transdermal patches, and oral thin films, offering end-to-end services from feasibility studies to clinical trial supply production. The company leverages advanced technologies such as hot-melt extrusion, drug printing, and amorphization of APIs to deliver comprehensive pharmaceutical solutions.
Committed to innovation, Gen-Plus collaborates with leading European research institutions and biotech companies to drive advancements in pharmaceutical solutions. The company's expertise and cutting-edge infrastructure make it a trusted partner in accelerating drug development and commercialization.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information is based on management's expectations, estimates, projections, and assumptions as of the date of this press release. It is subject to significant risks, uncertainties, and other factors that could cause actual results or events to differ materially from those expressed or implied. These risks and uncertainties include, but are not limited to, general economic conditions, market conditions, regulatory risks, technological advancements, and other factors described in the Company's public disclosure filings.
Readers are cautioned not to place undue reliance on forward-looking information, as actual outcomes may differ significantly from those expressed or implied, due to various factors beyond the Company's control. The Company undertakes no obligation to update or revise any forward-looking information, except as required by law.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
FAQ
When will BNXTF begin operations at the new Gen-Plus facility in Munich?
What is the size of BNXTF's new research facility at Gen-Plus?
What are the main research areas BNXTF will focus on at the Gen-Plus facility?
What specialized capabilities does the new Gen-Plus facility offer BNXTF?
